Urinary concentrations of phenols and parabens and incident diabetes in midlife women

The Study of Women’s Health Across the Nation

Seulbi Leea, Carrie Karvonen-Gutierrez,a Bhramar Mukherjeeb, William H. Hermanac, Siobán D. Harlowa, Sung Kyun Parkd,*

Background: Environmental phenols have been suggested as diabetogens but evidence from prospective cohort studies is limited. We examined associations between urinary concentrations of phenols and parabens, assessed at two time-points, and incident diabetes in the Study of Women's Health Across the Nation (SWAN).

Methods: We examined 1,299 women, aged 45–56 years, who were diabetes-free at baseline of the SWAN Multi-Pollutant Study (MPS) (1999–2000) and were followed through January 2017. Urinary concentrations of bisphenol-A, bisphenol-F, triclosan, 2,4-dichlorophenol, 2,5-dichlorophenol, benzophenone-3, methyl-paraben, ethyl-paraben, propyl-paraben, and butyl-paraben were measured twice at MPS baseline and 3 years later (2002–2003), and the two average concentrations were used as exposure variables. Associations of incident diabetes with individual phenols and parabens were examined using Cox regression. We evaluated the overall joint effects using quantile-based g-computation.

Results: Adjusted hazard ratios (HRs) for incident diabetes of the third tertile compared with the first tertile of urinary concentrations were 0.40 (95% confidence interval [CI] = 0.29, 0.56) for methyl-paraben; 0.42 (0.30, 0.58) for propyl-paraben; 0.53 (0.38, 0.75) for 2,5-dichlorophenol; and 0.55 (0.39, 0.80) for benzophenone-3. Nonlinear associations were found for bisphenol-A and 2,4-dichlorophenol (significant positive associations in the second tertile but no associations in the third tertile compared with the first tertile). No significant associations were observed for the other individual chemicals or the joint effect of mixtures.

Conclusions: Our findings do not support diabetogenic effects of urinary parabens which were inversely associated with incident diabetes among mid-life women. Epidemiologic findings for biomarkers with short half-lives and high within-person variability need to be interpreted with caution.

Keywords: Environmental phenols; Parabens; Diabetes; Midlife women; Mixture

Introduction

Diabetes is one of the fastest growing public health problems worldwide. In 2019, the International Diabetes Federation estimated that 463 million people (9.3% of adults with 20–79 years of age) suffered from diabetes globally with the number expected to increase to 700 million by 2045 (type 1 and type 2 combined of which approximately 90% are type 2).1 Type 2 diabetes mellitus (T2DM), characterized by high blood sugar caused by insulin resistance and relative insulin deficiency, increases the risk of developing cardiovascular disease, renal disease, neurologic disorders, and certain cancers.2 Recent studies suggest that endocrine-disrupting chemicals (EDCs) including phenols and parabens, may play a role in the etiology of T2DM.3

What this study adds

We investigated the association between urinary concentrations of phenols and parabens and incident diabetes using a large prospective cohort study of midlife women. Urinary phenols and parabens were assessed at two time-points, which allows us to evaluate reliability of the associations and account for within-person variability. We found inverse associations between average concentrations of urinary parabens and incident diabetes. We found nonlinear associations for average concentrations of urinary bisphenol-A and 2,4-dichlorophenols and incident diabetes (significant positive associations in the second tertile but no associations in the third tertile compared with the first tertile). Additionally, we found no significant association for the overall joint effect of phenols and parabens as mixtures using quantile-based g-computation.
Environmental phenols and parabens are synthetic chemicals extensively used in personal care and consumer products. For example, bisphenol A (BPA) and its analogues, such as bisphenol S (BPS) and bisphenol F (BPF), are used in polycarbonate plastics and epoxy resins to coat the interior of food cans and food and beverage storage containers. Triclosan are broad spectrum antibacterial agents added to soaps, toothpastes, and underarm deodorants. Parabens are mainly used as antimicrobial preservatives in cosmetics. Benzophenone-3, an ultraviolet (UV) filter, is widely used in sunscreen products. 2,5-dichlorophenol is a major metabolite of 1,4-dichlorobenzene, which has been used for mothballs and space deodorants. 2,4-dichlorophenol is used in the production of phenoxy acid herbicides such as 2,4-diphenoxycetic acid.

Previous experimental studies suggest several potential underlying mechanisms between BPA exposure and diabetes. BPA may increase the risk of diabetes through insulin resistance, disrupted gluconeogenesis, pancreatic beta-cell dysfunction, or impaired insulin secretion. Furthermore, recent studies have found that BPS and BPF, BPA alternatives, can be hormonally active as BPA. Experimental evidence for other phenols and parabens and diabetes is very limited. Phenols and parabens interfere with estrogens and androgens by binding to the extracellular face of membrane-bound receptors or by diffusing across cell membranes and binding to intracellular receptors. Phenols and parabens also activate the expression of peroxisome proliferator-activated receptor-γ (PPARγ) and promote adipogenesis which can affect glucose homeostasis.

Previous epidemiological studies, conducted mostly in cross-sectional settings, reported that higher urinary bisphenols and 2,5-dichlorophenol concentrations were associated with a higher risk of diabetes, whereas higher urinary parabens and benzophenone-3 concentrations were associated with lower risk of diabetes. However, information based on prospective designs is limited, raising concerns related to causal inference and problems of reverse causality. One longitudinal study reported that urinary concentrations of BPA were associated with higher risk of T2DM in the Nurses Health cohorts. One French study reported that urinary concentrations of BPA and BPS were associated with incident T2DM. No previous prospective study has investigated the effects of other phenols and parabens on incident diabetes. In addition, most studies used phenol and paraben concentrations evaluated at only one point in time, raising concerns of measurement error.

Herein, we examined the associations between urinary concentrations of phenols and parabens and incident diabetes in a multi-site, multiethnic prospective cohort of middle-aged women in the Study of Women’s Health Across the Nation (SWAN). Although the types of diabetes were not determined in our study, incident diabetes cases during this life stage are overwhelmingly T2DM and truly identifying type 1 cases is difficult due to the co-occurrence of many T2DM-related risk factors. Urinary phenols and parabens were assessed at two time points, three years apart, to evaluate consistency of the findings.

We conducted an exploratory analysis to evaluate the overall joint effects of phenols and parabens as mixtures given that no standard approach for mixture effects in relation to time-to-event data is available yet.

Methods

Study population

SWAN is a multisite, multiethnic, community-based longitudinal study designed to evaluate the effect of menopausal transition on women’s health and to identify risk factors for age-related chronic diseases. Between 1996 and 1997, 3,302 women were recruited from seven study sites, namely Boston, MA; Chicago, IL; southeast Michigan, MI; Los Angeles, CA; Oakland, CA; Newark, NJ; and Pittsburgh, PA. White women from all sites and women from one specified minority group in each site were enrolled (Black women from Boston, Chicago, Southeast Michigan, and Pittsburgh; Chinese women from Oakland; Japanese women from Los Angeles; Hispanic women from Newark). Eligibility criteria for enrollment into the SWAN cohort included: age 42–52 years, intact uterus and at least one ovary, no use of exogenous hormones affecting ovarian function in the past 3 months, at least one menstrual period in the previous three months, and self-identification with the site’s designated racial/ethnic groups. Participants have undergone clinical examinations and laboratory tests near annually. Institutional Review Board approval was obtained at each study site, and all participants provided signed informed consent at each study visit.

The SWAN Multi-Pollutant Study (MPS) was designed to evaluate exposure to environmental chemicals, including environmental phenols and parabens, and metabolic diseases. The third SWAN follow-up visit was used as the MPS baseline with 1,400 women sampled for the SWAN MPS including 4 racial/ethnic groups (White, Black, Chinese, and Japanese) and 5 study sites (Boston, Pittsburgh, Southeast Michigan, Los Angeles, Oakland). For assessment of environmental phenols and parabens, we analyzed urine samples collected at MPS baseline and the third follow-up visits (1999–2000 [n = 1,400] and 2002–2003 [n = 1,386], respectively) to evaluate consistency of association for nonpersistent chemicals. For the present study, we excluded prevalent diabetes cases at the MPS baseline, missing data for urinary phenols, parabens, and creatinine concentrations at the two exposure measurements, yielding 1,299 participants for data analysis (eFigure 1; http://links.lww.com/EE/A154).

Assessment of urinary phenol and paraben concentrations

All specimens were collected and stored in the SWAN Repository (http://swanrepository.com/) using a systematic protocol: urine specimens were collected in a 50-mL sterile cup made from clear polypropylene before 9 am but were not the first voided urine. Although the urine did not need to be refrigerated between the time of collection and delivery to the study center that same morning, it was protected from direct sunlight by wrapping in brown paper bag to protect it from sunlight. After receiving the urine from the participant, it was immediately aliquoted into 0.5 mL vials, which were frozen and stored in ultra-low freezers at −80°C without thawing until they were analyzed for the phenol and paraben contents. A total of eight phenols (BPA, BPS, BPF, 2,4-dichlorophenol, 2,5-dichlorophenol, triclosan, triclocarbon, and benzophenone-3) and four parabens (methyl-paraben, ethyl-paraben, propyl-paraben, and butyl-paraben) were measured using online solid phase extraction coupled to high-performance liquid chromatography–isotope dilution tandem mass spectrometry (MS/MS) by the Applied Research Center of NSF International (Ann Arbor, Michigan), a part of the Michigan Children’s Health Exposure Analysis Resource (M-CHEAR) Laboratory Hub. We used the laboratory procedure manual published by the Centers for Disease
Control and Prevention (CDC) (Method 6301.01). The allowed percent deviation from nominal quality controls (QCs) values at all QC level is $\pm 2$ standard deviations of the mean of each QC level determined from historical QC data for each of the phenols and parabens in the method. The limits of detections (LODs) of urinary phenols, and paraben concentrations, ranged from 5.2 to 99.8% (Table 1 and eTable 1; http://links.lww.com/EE/A154) at both time points of exposure assessment. We excluded BPS and triclocarban because of low detection rate (5.2–17.3% for BPS and 9.5–11.4% for triclocarban), thus six phenols and four parabens were included in this study. Urinary phenols and parabens concentrations below LODs were not imputed with constants because of potential bias.23

Incident diabetes ascertainment
We used conservative criteria to ascertain incident diabetes to minimize outcome misclassification. A participant was considered to have incident diabetes if she met any of the following criteria during follow-up24–26: (1) use of an antidiabetic medication at any visit, (2) fasting glucose $\geq 126$ mg/dL on at least half of 3 attended visits or two consecutive visits, or (3) any two visits with self-reported diabetes and at least one visit with fasting blood glucose $\geq 126$ mg/dL. Diabetes cases were not distinguished between type 1 and type 2 in the SWAN, but the majority of diabetes cases after age 40 are T2DM.

Covariates
Sociodemographic factors including age, site, race/ethnicity, and educational attainment were assessed during the SWAN baseline examination (1996–1997). Since only one minority group was recruited from each site, a single combined site and race/ethnicity variable was created and used in data analysis. Education was categorized as high school diploma or less, some college, a four-year college, and graduate school or higher. Lifestyle variables included physical activity and smoking. Self-reported physical activity was collected at the MPS baseline and follow-up visit 3 and smoking status was collected at every visit using a self-administered questionnaire. Total physical activity score was based on the sum of each physical activity score in three domains (sports/exercise, household/caregiving, and daily routine), with scores in each domain ranging from 1 to 5 (total physical activity score ranged from 3 to 15 with 15 indicating the highest level of activity). Cigarette smoking was categorized as never, former, or current smoking. Menopause status and objectively measured body mass index (BMI) were also collected at every visit. Menopause status was determined from questions on bleeding patterns and categorized into premenopause, perimenopause, postmenopause, or current hormone use. Total caloric intake was collected at the SWAN baseline and visit 5, using a detailed semiquantitative food frequency questionnaire (FFQ) adopted from the Block FFQ. Urine creatinine, a maker of urine dilution, was determined using the Cobas Mira analyzer (HoriBA ABX, Montpellier, France).

Statistical analysis
Urinary phenol and paraben concentrations were divided by urinary creatinine concentration to adjust the urine volume.27 Spearman correlations coefficients between urinary creatinine-adjusted phenol and paraben concentrations and between the two measurement times were calculated and presented via correlation-matrix heat-maps. Creatinine-adjusted intraclass correlations (ICCs) of log-transformed urinary concentrations between two time-points (MPS baseline and three years later) were calculated using linear-mixed models. Based on the ICC, reliability of exposure marker was determined as poor (ICC $< 0.40$), fair (0.40 $\leq$ ICC $< 0.60$), good (0.60 $\leq$ ICC $< 0.75$), and excellent (ICC $\geq 0.75$).28 This criterion was used as the reliability indicator of the observed associations.

As participants in the SWAN-MPS cohort may differ from the original SWAN cohort, we assigned weights to participants based on inverse probability weighting (IPW) to create a pseudo population representative of the original cohort, to address potential selection bias (see eMethods; http://links.lww.com/EE/A154; for details of the inverse probability weighting method).

Table 1: Summary statistics of creatinine-adjusted urinary concentrations of phenols and parabens at MPS baseline (1999–2000) and MPS follow-up visit 3 (2002–2003)

|                  | Detection rate (%) | LOD | GM*  | GSD* | Percentiles         |
|------------------|--------------------|-----|------|------|---------------------|
|                  |                    |     |      |      | Min     | P50   | P95      | Max         |
| MPS baseline     |                    |     |      |      |                     |       |         |            |
| BPA              | 83.0               | 0.4 | 1.39 | 2.84 | $<$LOD  | 0.83  | 2.10    | 76.81       |
| BPF              | 73.7               | 0.4 | 0.99 | 2.86 | $<$LOD  | 0.53  | 1.41    | 56.87       |
| 2,4-dichlorophenol | 98.6               | 0.2 | 3.68 | 4.23 | $<$LOD  | 1.75  | 5.35    | 1,168.05    |
| 2,5-dichlorophenol | 99.8               | 0.2 | 12.79| 5.63 | $<$LOD  | 4.73  | 18.52   | 6,942.05    |
| Triclocan        | 81.1               | 2.0 | 17.23| 5.94 | $<$LOD  | 5.97  | 35.40   | 2,468.05    |
| Methyl-paraben   | 99.8               | 1.0 | 130.47| 4.66 | $<$LOD  | 79.64 | 297.26  | 4,440.59    |
| Ethyl-paraben    | 60.5               | 1.0 | 3.91 | 6.23 | $<$LOD  | 5.97  | 35.40   | 2,468.05    |
| Propyl-paraben   | 97.8               | 0.2 | 22.64| 6.88 | $<$LOD  | 10.29 | 60.53   | 1,896.33    |
| Butyl-paraben    | 54.4               | 0.2 | 0.79 | 6.83 | $<$LOD  | 12.2  | 274.76  |            |
| Benzophenone-3   | 97.7               | 0.4 | 24.01| 12.18| $<$LOD  | 4.57  | 69.42   | 21,493.43   |
| MPS follow-up visit 3 |              |     |      |      |                     |       |         |            |
| BPA              | 93.4               | 0.4 | 1.77 | 2.40 | $<$LOD  | 1.21  | 2.40    | 333.35      |
| BPF              | 80.6               | 0.4 | 1.11 | 2.64 | $<$LOD  | 0.71  | 1.47    | 86.32       |
| 2,4-dichlorophenol | 99.0               | 0.2 | 2.01 | 3.53 | $<$LOD  | 1.06  | 2.35    | 902.32      |
| 2,5-dichlorophenol | 99.3               | 0.2 | 7.92 | 5.50 | $<$LOD  | 3.06  | 11.37   | 4,447.77    |
| Triclocan        | 82.9               | 2.0 | 16.04| 5.57 | $<$LOD  | 6.41  | 25.99   | 13,315.6    |
| Methyl-paraben   | 99.6               | 1.0 | 128.93| 4.61 | $<$LOD  | 81.02 | 269.30  | 11,504.72   |
| Ethyl-paraben    | 60.9               | 1.0 | 4.37 | 5.78 | $<$LOD  | 6.41  | 25.99   | 13,315.6    |
| Propyl-paraben   | 98.4               | 0.2 | 19.17| 6.74 | $<$LOD  | 8.67  | 55.86   | 2,760.12    |
| Butyl-paraben    | 59.3               | 0.2 | 0.95 | 6.91 | $<$LOD  | 10.29 | 60.53   | 1,896.33    |
| Benzophenone-3   | 97.7               | 0.4 | 33.28| 11.82| $<$LOD  | 7.72  | 92.09   | 41,715.0    |

*Geometric mean and geometric standard deviation was calculated after substituting values below LOD with LOD/$\sqrt{2}$. GM, geometric mean; GSD, geometric standard deviation; LOD, limit of detection; MPS, multipollutant study.
To examine the associations of incident diabetes with phenols and parabens individually, we used Cox proportional hazards models. Follow-up time was computed from MPS baseline to the date of first diabetes event, loss to follow-up, or the date of the final SWAN visit (16th follow-up visit in 2016–2017). The average concentrations of two exposure measurements were used as the primary exposure variables. As secondary analyses, we also used exposure concentrations measured at MPS baseline and at MPS follow-up visit 3 each as exposure variables. Visit-specific tertile cutoffs were used. We fitted exposure variables as tertiles instead of continuous because agreement of the rank orders across tertiles is relatively high-despite high within-person variations of these nonpersistent chemicals. All models were adjusted for age at baseline, site and ethnicity, education levels, physical activity score, menopausal status, smoking status, and total caloric intake. Education and menopausal status were treated as strata because these variables did not hold the proportional hazards assumption. All covariates were collected at the baseline of each exposure time point. Hazard ratios (HRs) and 95% confidence intervals (CIs) were computed comparing the second and the third tertiles with the first tertile. For the chemicals with detection rates < 2/3 (ethyl and butyl parabens), we dichotomized them at the LOD and compared women who had concentrations > LOD versus ≤ LOD.

To evaluate the overall joint effects of phenols and parabens as mixtures, we used a quantile based g-computation approach, which was recently proposed for addressing the effects of chemical mixture.29 Quantile based g-computation has certain advantages over other mixture approaches such as weighted quantile concentrations although controlling for covariates. For this analysis, we restricted the follow-up time up to 6 years with the assumption that exposure assessment was conducted at baseline and in the middle of follow-up. Finally, we examined the associations with continuous scales of urinary phenol and paraben concentrations. All analyses were conducted using SAS, version 9.3 (SAS Institute Inc.) and R, version 3.6.1 (R Core Team 2019).

Results

Study population

The characteristics of the study population at the MPS baseline stratified by incident diabetes are described in Table 2. During the SWAN follow-up after the MPS baseline (median = 16 years), 132 incident cases of diabetes were identified (incidence rate = 7.07 per 1,000 person-years; 95% CI = 5.93, 8.35). The average age of participants was 49.03 years (SD = 2.63); it was significantly higher in women with subsequent incident diabetes than those without incident diabetes (P < 0.001). Generally, women with incident diabetes were more likely to be physically inactive, consume more total caloric intake per day, and have higher BMI (characteristics at MPS follow-up visit 3 are presented in Table 2).

Urinary phenols and parabens

The distribution of urinary phenol and paraben concentrations and creatinine-adjusted phenol and paraben concentrations at MPS baseline and the follow-up visit 3 are provided in Table 1 and eTable 1; http://links.lww.com/EE/A154, respectively. In general, the phenol and paraben concentrations at the MPS follow-up visit 3 were lower than those at MPS baseline (Figure 2; http://links.lww.com/EE/A154). Figure 1 shows the Spearman correlation matrix of the log-transformed creatinine-adjusted phenol and paraben concentrations. Parabens and benzophenone-3 were modestly and positively correlated with each other at both visits but bisphenols were not correlated with each other. Creatinine-adjusted concentrations of urinary phenols and parabens were positively associated with BMI in the second tertile and HR = 1.77 (95% CI = 1.28, 2.46) for second tertile versus first tertile (p-for-trend: < 0.001) and HR = 1.37 (95% CI = 0.87, 2.13) for third tertile versus first tertile (p-for-trend: < 0.001). Additionally, an inverse association was observed with benzophenone-3 [HR = 0.80 (95% CI = 0.60, 1.07) for the second tertile and HR = 0.55 (95% CI = 0.39, 0.80) for the third tertile]. For BPA that had a poor reliability, a significant positive association was observed in the second tertile [HR = 1.67 (95% CI = 1.22, 2.28)] but not in third tertile [HR = 1.31 (95% CI = 0.94, 1.83)]. The significant positive association remained after adjustment for BMI [HR = 1.77 (95% CI = 1.28, 2.46) for second tertile; HR = 1.53 (95% CI = 1.08, 2.16) for third tertile] (Table 3; http://links.lww.com/EE/A154). Also, the association was robust after excluding menopausal status [HR = 1.68 (95% CI = 1.23, 2.30) for second tertile; HR = 1.37 (95% CI = 0.98, 1.90) for third tertile] (Table 4; http://links.lww.com/EE/A154). A positive association was also found for 2,4-dichlorophenol [HR = 1.63 (95% CI = 1.18, 2.23) for second tertile; HR = 1.28 (95% CI = 0.91, 1.80) for third tertile]. No statistically significant associations were found for other chemicals. Similar associations were found for parabens when concentrations at MPS baseline or the follow-up visit 3 were used as exposure variables but the associations for other chemicals were inconsistent depending on the exposure measurement timing (Table 3).
### Table 2
Characteristics of the study population at MPS-baseline, overall and by incident diabetes status (1999–2000)

| Characteristic                  | Total (N = 1,299) | No incident diabetes (N = 1,167) | Incident diabetic (N = 132) | P     |
|--------------------------------|-------------------|----------------------------------|----------------------------|-------|
| Age (years)                    | 49.03 ± 2.65      | 49.00 ± 2.65                     | 49.29 ± 2.73               | <0.001|
| Site                           |                   |                                  |                            | <0.001|
| Los Angeles                    | 349 (26.87)       | 325 (27.85)                      | 24 (18.18)                 |       |
| Oakland                        | 285 (21.94)       | 260 (22.28)                      | 25 (18.94)                 |       |
| Michigan                       | 234 (18.01)       | 191 (16.37)                      | 43 (32.58)                 |       |
| Pittsburgh                     | 218 (16.78)       | 191 (16.37)                      | 27 (20.45)                 |       |
| Boston                         | 213 (16.40)       | 200 (17.14)                      | 13 (9.85)                  |       |
| Race/ethnicity                 |                   |                                  |                            | <0.001|
| White                          | 672 (51.73)       | 620 (53.13)                      | 52 (39.39)                 |       |
| Black                          | 270 (20.79)       | 222 (19.02)                      | 48 (36.36)                 |       |
| Chinese                        | 161 (12.39)       | 146 (12.51)                      | 15 (11.36)                 |       |
| Japanese                       | 196 (15.09)       | 179 (15.34)                      | 17 (12.88)                 |       |
| Education levels               |                   |                                  |                            | 0.067 |
| High schools or less           | 223 (17.17)       | 199 (17.05)                      | 24 (18.18)                 |       |
| Some college                   | 409 (31.49)       | 364 (30.33)                      | 55 (41.67)                 |       |
| College                        | 325 (25.02)       | 300 (25.71)                      | 25 (18.94)                 |       |
| Postcollege                    | 335 (25.79)       | 308 (26.39)                      | 27 (20.45)                 |       |
| Missing                        | 7 (0.53)          | 6 (0.51)                         | 1 (0.76)                   |       |
| Physical activity score        | 7.86 ± 1.74       | 7.93 ± 1.75                      | 7.32 ± 1.61                | <0.001|
| Menopause status               |                   |                                  |                            | 0.127 |
| Premenopause                   | 155 (11.93)       | 147 (12.60)                      | 79 (59.85)                 |       |
| Perimenopause                  | 761 (58.58)       | 682 (58.44)                      | 20 (15.15)                 |       |
| Postmenopause                  | 179 (13.78)       | 159 (13.62)                      | 8 (6.06)                   |       |
| Hormone therapy                | 204 (15.70)       | 179 (15.34)                      | 25 (18.94)                 |       |
| Smoking status                 |                   |                                  |                            | 0.214 |
| Never                          | 819 (63.05)       | 743 (63.67)                      | 76 (57.58)                 |       |
| Former                         | 346 (26.64)       | 310 (26.52)                      | 36 (27.27)                 |       |
| Current                        | 133 (10.24)       | 113 (9.68)                       | 20 (15.15)                 |       |
| Missing                        | 1 (0.08)          | 1 (0.99)                         | 0 (0.00)                   |       |
| Total caloric intake (kcal/d)  | 1,808 ± 692       | 1,789 ± 687                      | 2,001 ± 709                | <0.001|
| Body mass index (kg/m²)        | 27.48 ± 6.87      | 26.86 ± 6.48                     | 33.07 ± 7.69               | <0.001|

Data are expressed as mean ± standard deviation (SD) or n (%).

---

**Figure 1.** Correlation coefficients matrix between log-transformed creatinine-adjusted urinary phenol and paraben concentrations at MPS baseline (1999–2000) and MPS follow-up visit 3 (2002–2003). The color intensity of boxes indicates the magnitude of correlation. Blue and red colors represent positive and negative correlations, respectively. BPA, bisphenol A; BPF, bisphenol F; MPS, multipollutant study.
Table 3. Adjusted hazard ratios for incident diabetes comparing the second and the third tertiles with the first tertile of creatinine-adjusted urinary phen and paraben concentrations

| Chemical       | Reliability of exposure marker | Tertile | Average^b | HR (95% CI) | P trend | MPS baseline^c | HR (95% CI) | P trend | MPS follow-up visit 3^d | HR (95% CI) | P trend |
|----------------|-------------------------------|---------|------------|-------------|---------|----------------|-------------|---------|-------------------------|-------------|---------|
| BPA            | Poor                          | T2      | 1.67       | 1.22, 2.28  | 0.10    | 1.26           | 0.94        | 0.94    | 1.08                    | 0.74, 1.58  | 0.17    |
|                |                               | T3      | 1.31       | 0.94, 1.83  | 0.96    | 0.96           | 1.29        | 1.29    | 0.89                    | 1.87        |         |
| BPF            | Poor                          | T2      | 1.27       | 0.93, 1.74  | 0.91    | 0.61           | 0.61        | 0.06    | 1.35                    | 0.94, 1.94  | 0.45    |
|                |                               | T3      | 1.01       | 0.74, 1.37  | 0.77    | 0.57           | 0.77        | 1.35    | 0.79                    | 1.65        |         |
| 2,4-dichlorophenol | Poor                      | T2      | 1.63       | 1.18, 2.23  | 0.20    | 1.65           | 0.10        | 0.10    | 0.94                    | 0.64, 1.36  | 0.67    |
|                |                               | T3      | 1.28       | 0.91, 1.80  | 1.36    | 0.98           | 0.92        | 0.92    | 0.92                    | 1.33        |         |
| 2,5-dichlorophenol | Fair                      | T2      | 0.82       | 0.60, 1.13  | <0.001  | 0.83           | <0.001      | <0.001  | 0.80                    | 0.54, 1.18  | 0.12    |
|                |                               | T3      | 0.53       | 0.38, 0.79  | 0.38    | 0.63           | 0.72        | 0.69    | 0.70                    | 0.48, 1.01  |         |
| Triclosan      | Poor                          | T2      | 0.99       | 0.72, 1.36  | <0.001  | 1.31           | <0.001      | <0.001  | 1.09                    | 0.77, 1.55  | 0.02    |
|                |                               | T3      | 1.14       | 0.84, 1.56  | 1.07    | 0.73           | 0.89        | 0.69    | 0.70                    | 0.62, 1.28  |         |
| Methyl-paraben | Fair                          | T2      | 0.67       | 0.50, 0.89  | <0.001  | 0.61           | <0.001      | <0.001  | 0.52                    | 0.34, 0.78  |         |
|                |                               | T3      | 0.40       | 0.29, 0.56  | 0.38    | 0.38           | 0.52        | 0.52    | 0.61                    | 0.37, 1.04  |         |
| Ethyl-paraben  | Fair                          | ≥ LOD^e | 0.49       | 0.38, 0.64  | <0.001  | 0.52           | <0.001      | <0.001  | 0.59                    | 0.44, 0.81  |         |
| Propyl-paraben | Fair                          | ≥ LOD^e | 0.60       | 0.44, 0.80  | <0.001  | 0.67           | <0.001      | <0.001  | 0.73                    | 0.52, 1.04  |         |
| Butyl-paraben  | Fair                          | ≥ LOD^e | 0.42       | 0.30, 0.58  | 0.36    | 0.25           | 0.60        | 0.60    | 0.60                    | 0.41, 0.87  |         |
| Benzenophene-3 | Fair                          | ≥ LOD^e | 0.61       | 0.47, 0.79  | <0.001  | 0.82           | <0.001      | <0.001  | 0.65                    | 0.48, 0.88  |         |
|                |                               | T2      | 0.80       | 0.60, 1.07  | 0.001   | 1.17           | 0.65        | 0.65    | 0.88                    | 0.62, 1.24  | 0.13    |
|                |                               | T3      | 0.55       | 0.39, 0.80  | 0.81    | 0.57           | 0.74        | 0.74    | 0.49                    | 1.10        |         |

All models were adjusted for age at baseline, site and ethnicity, education levels, physical activity score, menopausal status, smoking status, and total caloric intake. Statistically significant (P < 0.05) HRs (95% CI) were in bold.

^bReliability of exposure marker was determined by intraclass correlation (ICC); poor (ICC < 0.40), fair (0.40 ≤ ICC < 0.60), good (0.60 ≤ ICC < 0.75), and excellent (ICC ≥ 0.75).

^cModels with average of exposures at MPS baseline and follow-up visit 3 were followed from MPS baseline to final SWAN visit.

^dModels with exposures at MPS baseline were followed from MPS baseline to final SWAN visit.

^eModels with exposures at MPS follow-up visit 3 were followed from MPS follow-up visit 3 to final SWAN visit.

These chemicals were dichotomized at the limit of detections because of low detections.

BPF, bisphenol F; BPA, bisphenol A.

In sensitivity analyses, the results were essentially unchanged when inverse probability weighting was not used (eTable 5; http://links.lww.com/EE/A154); creatinine-unadjusted urinary phenols and parabens were used (eTable 6; http://links.lww.com/EE/A154); and continuous urinary concentrations of phenols and parabens instead of tertiles were used (eTable 7; http://links.lww.com/EE/A154). Results for BPA, 2,4 dichlorophenol, parabens, and benzophene-3 remained unchanged when follow-ups were restricted through up to 6 years but the associations for 2,5-dichlorophenol and triclosan were changed (HR = 1.76 (95% CI = 1.06, 2.93) for second tertile and 0.77 (95% CI = 0.41, 1.45) for third tertile of 2,5-dichlorophenol; HR = 1.80 (95% CI = 1.14, 2.84) for second tertile and 0.96 (95% CI = 0.57, 1.62) for third tertile of triclosan) (eTable 8; http://links.lww.com/EE/A154).

Overall joint effect of urinary phenol and paraben mixture on incident diabetes

Individual log HRs for incident diabetes per one tertile increase in each linear, quadratic, and pairwise interaction terms of phenol and paraben tertiles (treated as continuous) from the quintile-based g-computation approach are presented in eFigure 3; http://links.lww.com/EE/A154. The directions of the associations with incident diabetes were in line with those of single pollutant models. The overall joint effect was not statistically significant (Figure 2) (HR = 0.79 (95% CI = 0.33, 1.91)). The predicted survival probability when all phenol and paraben concentrations were set at the first tertiles more rapidly decreased over the follow-up than the predicted survival probability when all phenol and paraben concentrations were set at the third tertiles (Figure 2).

Discussion

This study examined the associations between urinary concentrations of six phenols and four parabens with incident diabetes in a multiracial/ethnic, community-based cohort of midlife women in the United States, using repeated phenol and paraben concentrations measured three years apart. We observed inverse associations of parabens, 2,5-dichlorophenol, and benzophenone-3 with incident diabetes. In contrast, we observed nonlinear associations of BPA and 2,4-dichlorophenol with incident diabetes (significant positive associations in the second tertile but no associations in the third tertile compared with the first tertile). The sensitivity analyses suggested that the observed associations for parabens were robust whereas those for other chemicals were inconsistent. These findings suggest that exposure to parabens may be associated with lower risk of incident diabetes. Epidemiologic findings for biomarkers with short half-lives and high within-person variability need to be interpreted with caution.

Phenols and parabens are nonpersistent compounds with short half-lives that are excreted from the human body within 24–48 hours.32–35 Urinary concentrations of these chemicals have high ability need to be interpreted with caution.

for biomarkers with short half-lives and high within-person variability over time and the ICCs of urinary phenols and parabens generally range from 0.2 to 0.7.36–38 A study reported that estimations obtained from an epidemiological
study using chemicals with an ICC of 0.6 or less may be biased and weakly powered if chemical concentrations are determined from a single spot urine. To address this problem, we measured the urinary phenol and paraben concentrations at two time-points and used the average concentrations across the two-time points as exposure variables. Although our exposure assessment at two time-points is a strength, it was insufficient for some chemicals, such as bisphenols and 2,4-dichlorophenol, to make valid causal inference. However, the results were relatively stable when we restricted the follow-up up to 6 years.

We found inverse associations between parabens and incident diabetes. Previous studies in adults found ICCs of parabens ranged from 0.4 to 0.7, and ICCs for parabens were generally higher than that for BPA, which is also in line with our findings. Only a few studies have examined the association between parabens and diabetes. A case-control study of phenolic chemicals and T2DM in Saudi Arabia (N = 101) showed that the odds ratios (ORs) for diabetes diagnosis were significantly higher for the fourth quartile of urinary concentrations compared with the first quartile [OR = 9.21 (95% CI = 2, 86) lower prevalence of metabolic syndrome among women. These inverse associations are biologically plausible. Antiandrogenic and estrogenic properties of parabens have been reported. Estrogens are important for maintaining body weight and metabolic health, can promote healthier types of fat, and protect against insulin resistance. Furthermore, parabens also act as an agonist for PPARγ. PPARγ agonists improve glucose homeostasis through systemic insulin sensitization or the direct action of PPARγ on the transcription of genes involved in glucose disposal. Some animal and in vitro studies have observed that high dose paraben exposure (50–200 µM) made an adipogenic effect by activating glucocorticoid receptors (GR) and PPARγ. However, the concentrations capable of inducing the adipogenic effect was high compared with the concentrations observed in the human studies (10–80 nM). Thus, paraben concentrations at levels measured in human tissue may activate PPARγ and estrogen receptors leading to antiobesogenic and antidietogenic effects, while higher concentrations may activate GR and suppress PPARγ leading to adipogenic effects.

Previous epidemiologic studies of the association between BPA and diabetes have yielded inconsistent results. Numerous cross-sectional studies have reported a positive association between BPA and prevalence of diabetes, whereas others have failed to detect an association. Findings from the few prospective studies have not been consistent. Two studies of incident T2DM with BPA measured at a single point also reported nonsignificant associations. A third longitudinal study (N = 755) with BPA concentrations measured at two time points, similar to our study, reported a positive association between the BPA concentrations measured at the later time point and incident T2DM, similar to our findings. Urinary BPA concentrations are known to have within-person variability with the range of ICCs of approximately 0.04–0.2 in line with our results. This low reliability indicates that a single BPA measurement is not adequate to approximate typical exposure, resulting in attenuation bias with significant loss of powers. According to a simulation study, the bias in the effect estimate is over 60% when a chemical with an ICC of 0.2 is measured twice. Despite
having two urine samples measured 3 years apart in our study, inconsistent findings suggest that two samples may be insufficient to account for exposure measurement error. Additionally, the discordant associations between 2,4- (inconsistent) and 2,5-dichlorophenol (consistent associations between two time points) may be due to the poor reliability of urinary 2,4-dichlorophenol concentrations (ICC = 0.3) compared with 2,5-dichlorophenol concentrations (ICC = 0.59).

To the best of our knowledge, this is the first study to examine the overall joint effect associated with phenols and parabens mixtures. We found no significant overall joint effects utilizing the quantile-based g-computation approach. This may be because the associations for individual phenols and parabens were in opposite directions and offset each other. The major strengths of the quantile-based g-computation approach. This may be because continuous chemical concentration variables are categorized into quantiles. Other statistical approaches for time-to-event outcome, such as Cox penalized regression model and random survival forests, were not used in the present study because those approaches were not designed to evaluate the overall joint effects of the mixture.

The present study has several limitations. First, although our exposure assessment for urinary biomarkers of short half-life chemicals at two time-points is a strength, some chemicals with low ICCs, such as bisphenols and 2,4-dichlorophenol, were still subject to exposure measurement errors. Second, since urine samples were collected up to 20 years ago, which allowed us to evaluate incident diabetes prospectively, the urinary concentrations used in the present study reflect exposure levels at the time of collection (from 1999 to 2003) but do not reflect current population exposure levels. Finally, although we adjusted for many potential confounding factors in this study, residual and unmeasured confounding cannot be ruled out, especially for the inverse association between parabens and incident diabetes. Parabens are commonly used as preservatives in medications and food supplements, which may reduce the risk of developing diabetes.

In conclusion, our findings do not support diabetogenic effects of parabens, which were inversely associated with incident diabetes among mid-life women. Epidemiologic findings for biomarkers with short half-lives and high within-person variability need to be interpreted with caution. Proper exposure assessment for chemicals with low reliability needs to be considered during the design of future studies to evaluate diabetogenic effects of phenols and parabens.

**Conflicts of interest statement**

The authors declare that they have no conflicts of interest with regard to the content of this report.

**Acknowledgments**

Clinical Centers: University of Michigan, Ann Arbor—Siobán Harlow, PI 2011–present, MaryFran Sowers, PI 1994–2011; Massachusetts General Hospital, Boston, MA—Joel Finkelstein, PI 1999–present; Robert Neer, PI 1994–1999; Rush University, Rush University Medical Center, Chicago, IL—Howard Krakow, PI 2009–present; Lynda Powell, PI 1994–2009; University of California, Davis/Kaiser—Ellen Gold, PI; University of California, Los Angeles—Gail Greendale, PI; Albert Einstein College of Medicine, Bronx, NY—Carol Derby, PI 2011–present; Rachel Wildman, PI 2010–2011; Nanette Santoro, PI 2004–2010; University of Medicine and Dentistry—New Jersey Medical School, Newark—Gerson Weiss, PI 1994–2004; and the University of Pittsburgh, Pittsburgh, PA—Karen Matthews, PI.

NIH Program Office: National Institute on Aging, Bethesda, MD—Chhanda Dutta 2016–present; Winifred Rossi 2012–2016; Sherry Sherman 1994–2012; Marcia Ory 1994–2001; National Institute of Nursing Research, Bethesda, MD—Program Officers.

Central Laboratory: University of Michigan, Ann Arbor—Daniel McConnell (Central Ligand Assay Satellite Services). SWAN Repository: University of Michigan, Ann Arbor—Siobán Harlow 2013–Present; Dan McConnell 2011–2013; MaryFran Sowers 2000–2011.

Coordinating Center: University of Pittsburgh, Pittsburgh, PA—Maria Mori Brooks, PI 2012–present; Kim Sutton-Tyrrrell, PI 2001–2012; New England Research Institutes, Watertown, MA—Sonja McKinlay, PI 1995–2001.

Steering Committee: Susan Johnson, Current Chair; Chris Gallagher, Former Chair.

We thank the study staff at each site and all the women who participated in SWAN.

**References**

1. Saedi P, Petersohn I, Salpea P, et al; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.

2. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88–98.

3. Neel BA, Sargis RM. The paradox of progress: environmental disruption of metabolism and the diabetes epidemic. Diabetes. 2011;60:1838–1848.

4. Chen D, Kannan K, Tan H, et al. Bisphenol analogues other than BPA: environmental occurrence, human exposure, and toxicity-A review. Environ Sci Technol. 2016;50:5438–5453.

5. Bhargava HN, Leonard PA. Triclosan: applications and safety. Am J Infect Control. 1996;24:209–218.

6. Dailey PD, Harvey PW. Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks. J Appl Toxicol. 2008;28:561–578.

7. Gustavsson Gonzalez H, Farbrot A, Larko O. Percutaneous absorption of benzophenone-3, a common component of topical sunscreens. Clin Exp Dermatol. 2002;27:691–694.

8. Ye X, Hong LY, Zhou X, Calafat AM. Urinary concentrations of 2,4-dichlorophenol and 2,4-dichlorophenol in the U.S. population (National Health and Nutrition Examination Survey, 2003-2010): trends and predictors. Environ Health Perspect. 2014;122:351–355.

9. Alonso-Magdalena P, Quesada I, Nadal A. Endocrine disruptors in the etiology of type 2 diabetes mellitus. Nat Rev Endocrinol. 2011;7:346–353.

10. Rochester JR, Bolden AL. Bisphenol S and F: a systematic review and their effects on the endocrine system. J Expo Sci Environ Epidemiol. 2018;474:238–251.

11. Taxvig C, Dreisig K, Boberg J, et al. Differential effects of environmental chemicals and food contaminants on adipogenesis, biomarker release and PPARγ activation. Mol Cell Endocrinol. 2012;361:106–115.

12. González-Casanova JF, Pertiuz-Cruz SL, Caicedo-Ortega NH, Rojas-González DM. Adipogenesis, regulation and endocrine disruptors: emerging insights in obesity. Biomed Res Int. 2020;2020:7453786.

13. Wei Y, Zhuo J. Urinary concentrations of 2,5-dichlorophenol and diabetes in US adults. J Expo Sci Environ Epidemiol. 2016;26:329–333.

14. Duan Y, Yao Y, Wang B, et al. Association of urinary concentrations of bisphenols with type 2 diabetes mellitus: a case-control study. Environ Pollut. 2018;243(pt B):1771–1776.

15. González-Casanova JF, Pertiuz-Cruz SL, Caicedo-Ortega NH. Urinary phenols and parabens and diabetes among US adults, NHANES 2005–2014. Nutr Metab Cardiovasc Dis. 2020;30:768–776.

16. Kim J, Chevrier J. Exposure to parabens and prevalence of obesity and metabolic syndrome: an analysis of the Canadian Health Measures Survey. Sci Total Environ. 2020;713:135116.

17. Sun Q, Cornelis MC, Townsend MK, et al. Association of urinary concentrations of bisphenol A and phthalate metabolites with risk of type 2
diabetes: a prospective investigation in the Nurses' Health Study (NHS) and NHSII cohort. *Environ Health Perspect*. 2014;122:616–623.

20. Rancière F, Bottom J, Slama R, et al; D.E.S.I.R. Study Group. Exposure to bisphenol A and bisphenol S and incident type 2 diabetes: a case-control study in the French Cohort D.E.S.I.R. *Environ Health Perspect*. 2019;127:107013.

21. Thomas NJ, Jones SE, Weedon MN, Shields BM, Oram RA, Hattersley AT. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. *Lancet Diabetes Endocrinol*. 2018;6:122–129.

22. Sowers M, Crawford S, Sternfeld B, et al. SWAN: a multi-center, multi-ethnic, community-based cohort study of women and the menopausal transition. In: Lobo RA, Kelsey J, Marcus R, eds. *Menopause: Biology and Pathobiology*. Academic Press; 2000:175–188.

23. Nie L, Chu H, Liu C, Cole SR, Vexler A, Schisterman EF. Linear regression with an independent variable subject to a detection limit. *Epidemiology*. 2010;21(suppl 4):S17–S24.

24. Wang X, Karvonen-Gutierrez CA, Herman WH, Mukherjee B, Harlow SD, Park SK. Urinary metals and incident diabetes in middle-aged women: study of Women's Health Across the Nation (SWAN). *BMJ Open Diabetes Res Care*. 2020;8:e001233.

25. Reeves AN, Elliott MR, Brooks MM, et al. Symptom clusters predict risk of metabolic-syndrome and diabetes in middle age: the Study of Women's Health Across the Nation. *Ann Epidemiol*. 2021;58:48–55.

26. Karvonen-Gutierrez CA, Peng Q, Peterson M, Duchowky K, Nan B, Harlow S. Low grip strength predicts incident diabetes among mid-life women: the Michigan Study of Women's Health Across the Nation. *Age Ageing*. 2018;47:683–691.

27. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. *Environ Health Perspect*. 2005;113:192–200.

28. Cicchetti DV. The precision of reliability and validity estimates revisited. *J Clin Exp Neuropsychol*. 2001;23:695–700.

29. Keil AP, Buckley JP, O'Brien KM, Ferguson KK, Zhao S, White AJ. A quantile-based g-computation approach to addressing the effects of exposure mixtures. *Environ Health Perspect*. 2020;128:47004.

30. Carrico C, Gennings C, Wheeler DC, Factor-Litvak P. Characterization of weighted quantile sum regression for highly correlated data in a risk analysis setting. *J Agric Biol Environ Stat*. 2015;20:100–120.

31. van den Dries NNM, Werder E, Buckley J, O'Brien K. The qgcomp package: g-computation on exposure quantiles. Available at: https://cran.r-project.org/web/packages/qgcomp/vignettes/qgcomp-vignette.html. Accessed 5 October 2020.

32. Janjua NR, Frederiksen H, Skakkebaek NE, Wulf HC, Andersson AM. Urinary excretion of phthalates and paraben after repeated whole-body topical application in humans. *Int J Androl*. 2008;31:118–130.

33. Gonzalez H, Farbrot A, Larkö O, Wennberg AM. Percutaneous absorption of the sunscreen benzophenone-3 after repeated whole-body applications, with and without ultraviolet irradiation. *Br J Dermatol*. 2006;154:337–340.

34. Thayer KA, Doerge DR, Hunt D, et al. Pharmacokinetics of bisphenol A in humans following a single oral administration. *Environ Int*. 2015;83:107–115.

35. Sandborgh-Englund G, Adolfsson-Erici M, Ogham G, Ekstrand J. Pharmacokinetics of triclosan following oral ingestion in humans. *J Toxicol Environ Health A*. 2006;69:1861–1873.

36. Yazdy MM, Coull BA, Gardiner JC, et al. A possible approach to improving the reproducibility of urinary concentrations of phthalate metabolites and phenois during pregnancy. *J Expo Sci Environ Epidemiol*. 2018;28:448–460.

37. Meeker JD, Cantonwine DE, Rivera-González LO, et al. Distribution, variability, and predictors of urinary concentrations of phenois and parabens among pregnant women in Puerto Rico. *Environ Sci Technol*. 2013;47:3439–3447.

38. Pollack AZ, Perkins NJ, Spada R, et al. Variability and exposure classification of urinary phenol and paraben metabolite concentrations in reproductive-aged women. *Environ Res*. 2016;151:513–520.

39. Perrier F, Giorgis-Allemand L, Slama R, Philippe C. Within-subject pooling of biological samples to reduce exposure misclassification in biomarker-based studies. *Epidemiology*. 2016;27:378–388.

40. Li AY, Xue J, Lin S, et al. Urinary concentrations of environmental phenois and their association with type 2 diabetes in a population in Jeddah, Saudi Arabia. *Environ Res*. 2018;166:544–552.

41. Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism. *Adv Exp Med Biol*. 2017;1043:227–256.

42. Palmer BF, Clegg DJ. The sexual dimorphism of obesity. *Mol Cell Endocrinol*. 2015;402:113–119.

43. Kim HI, Ahn HY. Role of peroxisome proliferator-activated receptor-gamma in the glucose-sensing apparatus of liver and beta-cells. *Diabetes*. 2004;53(suppl 1):S63–S65.

44. Pereira-Fernandes A, Demaegdt H, Vandermeiren K, et al. Evaluation of a screening system for obesogenic compounds: screening of endocrine disrupting compounds and evaluation of the PPAR dependency of the effect. *PLoS One*. 2013;8:e77481.

45. van Meeuwen JA, van Son O, Piersma AH, de Jong PC, van den Berg M. Aromatase inhibiting and combined estrogenic effects of parabens and estrogenic effects of other additives in cosmetics. *Toxicol Appl Pharmacol*. 2008;230:372–382.

46. Ahmadkhaniha R, Mansouri M, Yunesian M, et al. Association of urinary bisphenol A concentration with type-2 diabetes mellitus. *J Environ Health Sci Eng*. 2014;12:64.

47. Hwang S, Lim JE, Choi Y, Jee SH. Bisphenol A exposure and type 2 diabetes mellitus risk: a meta-analysis. *BMJ Endocr Disord*. 2018;18:81.

48. Silver M, O’Neill MS, Sowers MR, Park SK. Urinary bisphenol A and type-2 diabetes in US adults: data from NHANES 2003-2008. *PLoS One*. 2011;6:e26868.

49. Kim K, Park H. Association between urinary concentrations of bisphenol A and type 2 diabetes in Korean adults: a population-based cross-sectional study. *Int J Hyg Environ Health*. 2013;216:467–471.

50. Shu X, Tang S, Peng C, et al. Bisphenol A is not associated with a 5-year incidence of type 2 diabetes: a prospective nested case-control study. *Acta Diabetol*. 2018;55:369–375.

51. Park SK, Tao Y, Meeker JD, Harlow SD, Mukherjee B. Environmental risk score as a new tool to examine multi-pollutants in epidemiologic research: an example from the NHANES study using serum lipid levels. *PLoS One*. 2014;9:e98632.

52. Park SK, Zhao Z, Mukherjee B. Construction of environmental risk score beyond standard linear models using machine learning methods: application to metal mixtures, oxidative stress and cardiovascular disease in NHANES. *Environ Health*. 2017;16:102.

53. Dodge LE, Kelley KE, Williams PL, et al. Medications as a source of paraben exposure. *Rep Toxicol*. 2015;52:93–100.